arrow
N

Nigel Clarke

University of Sheffield
H指数:46
被引数:7,409

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The STAMPEDE2 niraparib-abiraterone acetate plus prednisolone trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT)

STAMPEDE2尼拉帕利-阿比特龙醋酸盐联合泼尼松试验:一项在携带同源重组修复(HRR)基因有害变异、开始雄激素剥夺疗法(ADT)的转移性前列腺癌(mPC)患者中进行的III期、随机、开放标签试验

2024-09-010
PRE
Prostate cancer efficacy results from a randomised phase III evaluation of transdermal oestradiol (tE2) versus luteinising hormone releasing hormone agonists (LHRHa) for androgen suppression in non-metastatic (M0) prostate cancer

非转移性(M0)前列腺癌中,通过随机III期评估比较经皮雌二醇(tE2)与促黄体生成素释放激素激动剂(LHRHa)进行雄激素抑制的疗效结果。

2024-09-010
PRE
Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol
2021-09-018
OAAI
Liquid-liquid phase separation morphologies in ultra-white beetle scales and a synthetic equivalent
2019-08-2933
OAAI